Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05757141 · ClinicalTrials.gov registry record · Phase 1

An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease

A Phase 1 study of Vanishing White Matter Disease, sponsored by Calico Life Sciences.

Recruiting
Registry status
Phase 1
Development phase
50
Enrollment target
5
Study locations

NCT05757141 is a Phase 1 study of Vanishing White Matter Disease that is actively recruiting participants, run by Calico Life Sciences. The registered enrollment target is 50 participants. The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05757141, a Phase 1 study of Vanishing White Matter Disease, is actively recruiting participants, sponsored by Calico Life Sciences.

RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
5
Study locations

Study Summary

Fosigotifator is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult, pediatric and infant participants. This is a 201-week, open-label, multiple cohort study enrolling adults, pediatric and infant participants with Vanishing White Matter disease. Participants will attend regular visits during the course of the study and complete medical assessments, blood tests, questionnaires, and be evaluated for side effects.

Interventions

  • DRUG Fosigotifator

Study Locations (5)

Massachusetts

  • Massachusetts General Hospital /ID# 270960 - Boston

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Utah

  • University of Utah /ID# 255624 - Salt Lake City

Quebec

  • McGill University Health Centre - Glen Site - Montreal

North Holland

  • Amsterdam UMC, locatie VUmc /ID# 270955 - Amsterdam

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-03-13
Est. Completion 2029-11
Phase Phase 1

Sponsor

Calico Life Sciences

6 total trials

What the Registry Record Tells You About NCT05757141

The ClinicalTrials.gov registry entry for NCT05757141 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calico Life Sciences, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Vanishing White Matter Disease appearing as the primary indexed condition, and to 1 intervention - of which Fosigotifator is the first listed.

NCT05757141 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, Pennsylvania, Utah.

Frequently Asked Questions

What is clinical trial NCT05757141 about?

NCT05757141 is a clinical study titled "An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease". Fosigotifator is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult, pediatric and infant participants. This is a 201-week, open-label, multiple cohort study enrolling adults, pediatric and infant participants with Vanishing White Matter disease. P...

What is the current status of trial NCT05757141?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-03-13. Estimated completion is 2029-11.

What conditions does trial NCT05757141 study?

This clinical trial studies the following conditions: Vanishing White Matter Disease.

What interventions are being tested in trial NCT05757141?

The interventions under investigation include: Fosigotifator (DRUG).

Who is sponsoring clinical trial NCT05757141?

This trial is sponsored by Calico Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05757141 being conducted?

This trial has 5 study locations across Massachusetts, Pennsylvania, Utah, Quebec, North Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Vanishing White Matter Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.